<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02562326</url>
  </required_header>
  <id_info>
    <org_study_id>BC3-CT014</org_study_id>
    <nct_id>NCT02562326</nct_id>
  </id_info>
  <brief_title>A Trial to Investigate the Efficacy, Pharmacokinetics, Safety and Tolerability of BioChaperone Insulin Lispro in Comparison to Humalog® U-100 in Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Randomised, Monocentric, Double-blind, Multiple Daily Dose, Two-period 14 Day Cross-over Trial to Investigate the Efficacy, Pharmacokinetics, Safety and Tolerability of Individualised Doses of BioChaperone Insulin Lispro in Comparison to Humalog® U-100 in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adocia</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Adocia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, randomised, controlled, two-period crossover phase Ib trial using an
      individualised standard meal with a fixed nutrient ratio in subjects with type 2 diabetes
      mellitus to investigate post-prandial blood glucose control with BioChaperone insulin lispro
      compared to insulin lispro (Humalog®, Eli Lilly and Company) before and after a period of
      multiple daily dose administrations for 14 days. Each subject will be randomised to a
      sequence of two treatments, either BioChaperone insulin lispro-Humalog® or
      Humalog®-BioChaperone insulin lispro. Injections will take place immediately before an
      individualised standard meal in the morning of day 1, 2, 13, and 14. Insulin doses will be
      determined at the screening visit. During the outpatient phase the subjects will keep their
      basal insulin constant (except changes for safety reason). They will self-measure blood
      glucose at least 4 times daily (pre-prandial and at bedtime). In addition, on two days per
      outpatient period (Day 5 and 9) blood glucose will be measured 7 times daily (pre-prandial, 2
      hours post-prandial and at bedtime).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacodynamics: ΔAUCBG 0-2h</measure>
    <time_frame>2 hours</time_frame>
    <description>Incremental Area Under Blood Glucose concentration-time Curve from 0-2 hours after a meal (comparison between BioChaperone insulin lispro and insulin lispro)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: AUClis 0-30min</measure>
    <time_frame>30 minutes</time_frame>
    <description>Area Under the serum insulin Lispro concentration-time Curve 0-30 minutes (comparison between BioChaperone insulin lispro and insulin lispro)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUClisp_0-6h</measure>
    <time_frame>up to 6 hours</time_frame>
    <description>Area Under the serum insulin Lispro concentration-time Curve from 0-6 hours after bolus dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax_lisp</measure>
    <time_frame>up to 6 hours</time_frame>
    <description>Maximum serum insulin lispro Concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax_lisp</measure>
    <time_frame>up to 6 hours</time_frame>
    <description>Time to maximum observed serum insulin lispro concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CmaxBG</measure>
    <time_frame>up to 6 hours</time_frame>
    <description>Maximum Blood Glucose after an individualised standard meal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCBG_0-6h</measure>
    <time_frame>up to 6 hours</time_frame>
    <description>Area Under the Curve under the Blood Glucose concentration time curve from 0-6 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>Number of Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local tolerability</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>Record of injection site reaction</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>BioChaperone insulin lispro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Humalog®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BioChaperone insulin lispro</intervention_name>
    <description>Injection immediately before the start of the individualised standard meal</description>
    <arm_group_label>BioChaperone insulin lispro</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Humalog®</intervention_name>
    <description>Injection immediately before the start of the individualised standard meal</description>
    <arm_group_label>Humalog®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes mellitus ≥ 12 months

          -  Treated with stable multiple daily insulin ≥ 3 months (basal-bolus therapy or only
             bolus insulin therapy)

          -  Current total daily insulin treatment &lt;1.2 (I)U/kg/day

          -  Body Mass Index below or equal to 40.0 kg/m²

          -  HbA1c ≤ 9.0% by local laboratory analysis

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to trial products or related products

          -  Type 1 diabetes mellitus

          -  Previous participation in this trial

          -  The receipt of any investigational product within 60 days prior to this trial

          -  Clinically significant abnormal haematology, biochemistry, lipids, or urinalysis
             screening tests, as judged by the Investigator considering the underlying disease

          -  Presence of clinically significant acute gastrointestinal symptoms (e.g. nausea,
             vomiting, heartburn or diarrhoea), as judged by the Investigator

          -  Presence of renal impairment (Estimated Glomerular filtration Rate (eGFR)&lt;60
             milliliters/minute/1.73m²)

          -  Presence of late diabetic complications and/or acute coronary heart disease.

          -  Known slowing of gastric emptying and or gastrointestinal surgery that in the opinion
             of the investigator might change gastrointestinal motility and food absorption

          -  Unusual meal habits and special diet requirements or unwillingness to eat the food
             provided in the trial

          -  Current treatment with corticosteroids
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grit Andersen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Profil GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Profil Mainz GmbH &amp; Co.KG</name>
      <address>
        <city>Mainz</city>
        <zip>44116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Profil GmbH</name>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2015</study_first_submitted>
  <study_first_submitted_qc>September 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2015</study_first_posted>
  <last_update_submitted>April 28, 2016</last_update_submitted>
  <last_update_submitted_qc>April 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

